Shandong Weigao Group Medical Polymer Company Limited (“Weigao Group”) disclosed that it bought back 120,000 H shares on 11 June 2026 via on-market transactions on the Hong Kong Stock Exchange. The shares were repurchased at prices ranging from HK$3.33 to HK$3.35 each, with a volume-weighted average cost of HK$3.3383, for a total outlay of HK$0.40 million. All repurchased shares are being kept as treasury stock; none has been cancelled.

Following the transaction, Weigao Group’s outstanding share count (excluding treasury shares) slipped by 0.0027% to 4.46 billion, while the treasury-share balance increased to 57.99 million. The company’s total issued share capital remained unchanged at 4.52 billion shares.

The buyback was executed under a mandate approved on 29 May 2026, which authorises repurchases of up to 446.46 million shares. Cumulative repurchases under this mandate now stand at 660,000 shares, equivalent to 0.15% of the shares outstanding on the mandate date, leaving significant headroom for further action.

In line with Hong Kong listing rules, Weigao Group is subject to a moratorium on issuing new shares or disposing of treasury shares until 11 July 2026.